Software Segment Held Largest Share of Drug Modelling Software Market in 2019
According to the new market research study on “Middle East & Africa Drug Modelling Software Market to 2027 - Regional Analysis and Forecast - by Product Type, and Application” the market is expected to reach US$487.02 million by 2027 from US$297.94 million in 2019; it is estimated to grow at a CAGR of 6.6% from 2020 to 2027. The report provides trends prevailing in the Middle East & Africa drug modelling software market and the factors driving the market growth along with those hindering it.
In 2019, the software segment accounted for the highest share of the market. Also, the same segment is estimated to grow at the highest CAGR in the forecast period. Growth of this segment is attributed to the growing demand for effective therapeutics and increase in drug discovery efforts of various biologics across a wide range of therapeutics. In addition, strategic activities by service providers such as collaborations, product advancement, and product launch in order to expediate drug discovery timeline are further accelerating the growth of the market.
The growth of the Middle East & Africa drug modelling software market is mainly attributed to the rapid integration of AI for the drug discovery, increasing preference for personalized medicine, high R&D spending for novel therapeutic applications and presence of major market players. However, the less adoption in emerging countries is the major factor hindering the market growth in Middle East & Africa.
Compugen Ltd.; Biognos AB; Dassault Systèmes; Acellera; and Crown Bioscience Inc (JSR life science) are among the leading companies operating in the Middle East & Africa drug modelling software market.
The Report Segments Middle East & Africa Drug Modelling Software Market as Follows:
Middle East & Africa Drug Modelling Software Market - By Product Type
Middle East & Africa Drug Modelling Software Market - By Application
Middle East & Africa Drug Modelling Software Market - By Country
Reasons to Buy
According to the new market research study on “Middle East & Africa Drug Modelling Software Market to 2027 - Regional Analysis and Forecast - by Product Type, and Application” the market is expected to reach US$487.02 million by 2027 from US$297.94 million in 2019; it is estimated to grow at a CAGR of 6.6% from 2020 to 2027. The report provides trends prevailing in the Middle East & Africa drug modelling software market and the factors driving the market growth along with those hindering it.
In 2019, the software segment accounted for the highest share of the market. Also, the same segment is estimated to grow at the highest CAGR in the forecast period. Growth of this segment is attributed to the growing demand for effective therapeutics and increase in drug discovery efforts of various biologics across a wide range of therapeutics. In addition, strategic activities by service providers such as collaborations, product advancement, and product launch in order to expediate drug discovery timeline are further accelerating the growth of the market.
The growth of the Middle East & Africa drug modelling software market is mainly attributed to the rapid integration of AI for the drug discovery, increasing preference for personalized medicine, high R&D spending for novel therapeutic applications and presence of major market players. However, the less adoption in emerging countries is the major factor hindering the market growth in Middle East & Africa.
Compugen Ltd.; Biognos AB; Dassault Systèmes; Acellera; and Crown Bioscience Inc (JSR life science) are among the leading companies operating in the Middle East & Africa drug modelling software market.
The Report Segments Middle East & Africa Drug Modelling Software Market as Follows:
Middle East & Africa Drug Modelling Software Market - By Product Type
- Database
- Software
- Others
Middle East & Africa Drug Modelling Software Market - By Application
- Drug Discovery and Development
- Computational Physiological Medicine
- Disease Modelling
- Medical Imaging
- Predictive Analysis of Drug Targets
- Simulation Software
- Cellular Simulation
- Others
Middle East & Africa Drug Modelling Software Market - By Country
- Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa
Reasons to Buy
- It provides an understanding of the Middle East & Africa, drug modelling software market landscape and identifies drug modelling software market segments that are most likely to guarantee a strong return.
- Stay ahead of the race by comprehending the ever-changing competitive landscape for the Middle East & Africa drug modelling software market.
- It helps efficiently plan merger and acquisition, and partnership deals in the drug modelling software market by identifying market segments with the most promising probable sales
- It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of drug modelling software market performance of various segments pertaining to the Middle East & Africa drug modelling software market.
- It provides drug modelling software market revenue forecast of the market based on various segments for the period from 2019 to 2027.
Table of Contents
1. Introduction
3. Research Methodology
4. Middle East & Africa Drug Modelling Software Market - Market Landscape
5. Middle East & Africa Drug Modelling Software Market - Key Market Dynamics
6. Drug Modelling Software Market - Middle East & Africa Analysis
7. Middle East & Africa Drug Modelling Software Market Analysis and Forecasts To 2027 - By Product Type
8. Middle East & Africa Drug Modelling Software Market Analysis and Forecasts To 2027 - By Application
9. Drug Modelling Software Market Revenue and Forecasts To 2027 - Geographical Analysis
10. Impact of COVID-19 Pandemic on Middle East & Africa Drug Modelling Software Market
11. Company Profiles
12. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Crown Bioscience Inc (JSR life science)
- Compugen Ltd.
- Biognos AB
- Dassault Systèmes
- Acellera
